HTG Molecular Diagnostics, Inc. (HTGMQ)

HTG Molecular Diagnostics Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018
Revenue	3.47	6.37	8.91	8.55	19.2	21.5
Revenue Growth (YoY)	-48.97%	-28.52%	4.19%	-55.48%	-10.70%	45.69%
Cost of Revenue	3.18	4.57	4.09	3.99	8.91	5.09
Gross Profit	0.29	1.79	4.81	4.56	10.29	16.41
Selling, General & Admin	6.75	15.84	16.55	18.06	18.68	19.97
Research & Development	3.1	6.78	6.09	6.08	10.57	12.6
Other Operating Expenses	-0.04	0.01	-1.03	0.02	0	0
Operating Expenses	9.85	22.62	22.64	24.14	29.25	32.57
Operating Income	-9.56	-20.83	-17.82	-19.59	-18.96	-16.16
Interest Income	0.13	0.09	0.03	0.25	0.62	0.72
Interest Expense	0.31	0.86	1.06	1.02	0.96	0.9
Other Expense / Income	-0	-0.01	-1.74	0.5	-	0.11
Pretax Income	-9.74	-21.58	-17.12	-20.86	-19.29	-16.45
Income Tax	0.01	0.01	0.02	0.01	0	0
Net Income	-9.75	-21.59	-17.15	-20.87	-19.3	-16.45
Shares Outstanding (Basic)	-	1	1	0	0	0
Shares Outstanding (Diluted)	-	1	1	0	0	0
Shares Change	-	53.85%	49.88%	82.20%	38.43%	159.72%
EPS (Basic)	-4.40	-24.28	-29.66	-54.12	-91.17	-107.61
EPS (Diluted)	-4.40	-24.28	-29.66	-54.12	-91.17	-107.61
Free Cash Flow	-6.39	-18.43	-17.15	-16.75	-17.8	-14.12
Free Cash Flow Per Share	-	-20.73	-29.68	-43.42	-84.09	-92.37
Gross Margin	8.37%	28.18%	54.02%	53.31%	53.60%	76.33%
Operating Margin	-275.45%	-327.19%	-200.11%	-229.10%	-98.73%	-75.15%
Profit Margin	-280.76%	-339.20%	-192.49%	-244.13%	-100.49%	-76.52%
Free Cash Flow Margin	-184.14%	-289.51%	-192.58%	-195.88%	-92.68%	-65.68%
EBITDA	-9.43	-20.14	-19.56	-17.96	-16.6	-13.98
EBITDA Margin	-271.70%	-316.35%	-219.60%	-210.11%	-86.45%	-64.99%
Depreciation & Amortization	0.19	0.59	0.72	1.35	1.74	1.47
EBIT	-9.62	-20.73	-20.28	-19.31	-18.34	-15.44
EBIT Margin	-277.06%	-325.58%	-227.70%	-225.86%	-95.48%	-71.82%

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.